Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 57

1.

The RND1 Small GTPase: Main Functions and Emerging Role in Oncogenesis.

Mouly L, Gilhodes J, Lemarié A, Cohen-Jonathan Moyal E, Toulas C, Favre G, Sordet O, Monferran S.

Int J Mol Sci. 2019 Jul 24;20(15). pii: E3612. doi: 10.3390/ijms20153612. Review.

2.

Alpha6-Integrin Regulates FGFR1 Expression through the ZEB1/YAP1 Transcription Complex in Glioblastoma Stem Cells Resulting in Enhanced Proliferation and Stemness.

Kowalski-Chauvel A, Gouaze-Andersson V, Baricault L, Martin E, Delmas C, Toulas C, Cohen-Jonathan-Moyal E, Seva C.

Cancers (Basel). 2019 Mar 22;11(3). pii: E406. doi: 10.3390/cancers11030406.

3.

Germline mutation p.N363K in POLE is associated with an increased risk of colorectal cancer and giant cell glioblastoma.

Vande Perre P, Siegfried A, Corsini C, Bonnet D, Toulas C, Hamzaoui N, Selves J, Chipoulet E, Hoffmann JS, Uro-Coste E, Guimbaud R.

Fam Cancer. 2019 Apr;18(2):173-178. doi: 10.1007/s10689-018-0102-6.

PMID:
30368636
4.

RND1 regulates migration of human glioblastoma stem-like cells according to their anatomical localization and defines a prognostic signature in glioblastoma.

Boyrie S, Delmas C, Lemarié A, Lubrano V, Dahan P, Malric L, Luis J, Gilhodes J, Tosolini M, Mouly L, Lehmann M, Toulas C, Cohen-Jonathan Moyal E, Monferran S.

Oncotarget. 2018 Sep 18;9(73):33788-33803. doi: 10.18632/oncotarget.26082. eCollection 2018 Sep 18.

5.

Inhibiting Integrin β8 to Differentiate and Radiosensitize Glioblastoma-Initiating Cells.

Malric L, Monferran S, Delmas C, Arnauduc F, Dahan P, Boyrie S, Deshors P, Lubrano V, Da Mota DF, Gilhodes J, Filleron T, Siegfried A, Evrard S, Kowalski-Chauvel A, Moyal EC, Toulas C, Lemarié A.

Mol Cancer Res. 2019 Feb;17(2):384-397. doi: 10.1158/1541-7786.MCR-18-0386. Epub 2018 Sep 28.

PMID:
30266751
6.

FGFR1/FOXM1 pathway: a key regulator of glioblastoma stem cells radioresistance and a prognosis biomarker.

Gouazé-Andersson V, Ghérardi MJ, Lemarié A, Gilhodes J, Lubrano V, Arnauduc F, Cohen-Jonathan Moyal E, Toulas C.

Oncotarget. 2018 Aug 3;9(60):31637-31649. doi: 10.18632/oncotarget.25827. eCollection 2018 Aug 3.

7.

Alpha-6 integrin promotes radioresistance of glioblastoma by modulating DNA damage response and the transcription factor Zeb1.

Kowalski-Chauvel A, Modesto A, Gouaze-Andersson V, Baricault L, Gilhodes J, Delmas C, Lemarie A, Toulas C, Cohen-Jonathan-Moyal E, Seva C.

Cell Death Dis. 2018 Aug 29;9(9):872. doi: 10.1038/s41419-018-0853-x.

8.

By modulating α2β1 integrin signalling, gastrin increases adhesion oF AGS-GR gastric cancer cells.

Kowalski-Chauvel A, Teissier G, Toulas C, Cohen-Jonathan-Moyal E, Seva C.

Exp Cell Res. 2018 Jan 15;362(2):498-503. doi: 10.1016/j.yexcr.2017.12.014. Epub 2017 Dec 15.

PMID:
29253536
9.

Continuous Infusion of Cilengitide Plus Chemoradiotherapy for Patients With Stage III Non-Small-cell Lung Cancer: A Phase I Study.

Massabeau C, Khalifa J, Filleron T, Modesto A, Bigay-Gamé L, Plat G, Dierickx L, Aziza R, Rouquette I, Gomez-Roca C, Mounier M, Delord JP, Toulas C, Olivier P, Chatelut E, Mazières J, Cohen-Jonathan Moyal E.

Clin Lung Cancer. 2018 May;19(3):e277-e285. doi: 10.1016/j.cllc.2017.11.002. Epub 2017 Nov 21.

PMID:
29221762
10.

Interest of integrins targeting in glioblastoma according to tumor heterogeneity and cancer stem cell paradigm: an update.

Malric L, Monferran S, Gilhodes J, Boyrie S, Dahan P, Skuli N, Sesen J, Filleron T, Kowalski-Chauvel A, Cohen-Jonathan Moyal E, Toulas C, Lemarié A.

Oncotarget. 2017 Aug 21;8(49):86947-86968. doi: 10.18632/oncotarget.20372. eCollection 2017 Oct 17. Review.

11.

Targeting progastrin enhances radiosensitization of colorectal cancer cells.

Kowalski-Chauvel A, Gouaze-Andersson V, Vignolle-Vidoni A, Delmas C, Toulas C, Cohen-Jonathan-Moyal E, Seva C.

Oncotarget. 2017 Apr 20;8(35):58587-58600. doi: 10.18632/oncotarget.17274. eCollection 2017 Aug 29.

12.

BRCA Share: A Collection of Clinical BRCA Gene Variants.

Béroud C, Letovsky SI, Braastad CD, Caputo SM, Beaudoux O, Bignon YJ, Bressac-De Paillerets B, Bronner M, Buell CM, Collod-Béroud G, Coulet F, Derive N, Divincenzo C, Elzinga CD, Garrec C, Houdayer C, Karbassi I, Lizard S, Love A, Muller D, Nagan N, Nery CR, Rai G, Revillion F, Salgado D, Sévenet N, Sinilnikova O, Sobol H, Stoppa-Lyonnet D, Toulas C, Trautman E, Vaur D, Vilquin P, Weymouth KS, Willis A; Laboratory Corporation of America Variant Classification Group; Quest Diagnostics Variant Classification Group; UNICANCER Genetic Group BRCA Laboratory Network, Eisenberg M, Strom CM.

Hum Mutat. 2016 Dec;37(12):1318-1328. doi: 10.1002/humu.23113. Epub 2016 Sep 28.

13.

FGFR1 Induces Glioblastoma Radioresistance through the PLCγ/Hif1α Pathway.

Gouazé-Andersson V, Delmas C, Taurand M, Martinez-Gala J, Evrard S, Mazoyer S, Toulas C, Cohen-Jonathan-Moyal E.

Cancer Res. 2016 May 15;76(10):3036-44. doi: 10.1158/0008-5472.CAN-15-2058. Epub 2016 Feb 19.

14.

Genotyping of a family with a novel deleterious DPYD mutation supports the pretherapeutic screening of DPD deficiency with dihydrouracil/uracil ratio.

Thomas F, Hennebelle I, Delmas C, Lochon I, Dhelens C, Garnier Tixidre C, Bonadona A, Penel N, Goncalves A, Delord JP, Toulas C, Chatelut E.

Clin Pharmacol Ther. 2016 Feb;99(2):235-42. doi: 10.1002/cpt.210. Epub 2015 Nov 10.

PMID:
26265035
15.

Clinical relevance of 8q23, 15q13 and 18q21 SNP genotyping to evaluate colorectal cancer risk.

Baert-Desurmont S, Charbonnier F, Houivet E, Ippolito L, Mauillon J, Bougeard M, Abadie C, Malka D, Duffour J, Desseigne F, Colas C, Pujol P, Lejeune S, Dugast C, Buecher B, Faivre L, Leroux D, Gesta P, Coupier I, Guimbaud R, Berthet P, Manouvrier S, Cauchin E, Prieur F, Laurent-Puig P, Lebrun M, Jonveaux P, Chiesa J, Caron O, Morin-Meschin ME, Polycarpe-Osaer F, Giraud S, Zaanan A, Bonnet D, Mansuy L, Bonadona V, El Chehadeh S, Duhoux F, Gauthier-Villars M, Saurin JC, Collonge-Rame MA, Brugières L, Wang Q, Bressac-de Paillerets B, Rey JM, Toulas C, Buisine MP, Bronner M, Sokolowska J, Hardouin A, Cailleux AF, Sebaoui H, Blot J, Tinat J, Benichou J, Frebourg T.

Eur J Hum Genet. 2016 Jan;24(1):99-105. doi: 10.1038/ejhg.2015.72. Epub 2015 Apr 15.

16.

Metformin inhibits growth of human glioblastoma cells and enhances therapeutic response.

Sesen J, Dahan P, Scotland SJ, Saland E, Dang VT, Lemarié A, Tyler BM, Brem H, Toulas C, Cohen-Jonathan Moyal E, Sarry JE, Skuli N.

PLoS One. 2015 Apr 13;10(4):e0123721. doi: 10.1371/journal.pone.0123721. eCollection 2015.

17.

Ionizing radiations sustain glioblastoma cell dedifferentiation to a stem-like phenotype through survivin: possible involvement in radioresistance.

Dahan P, Martinez Gala J, Delmas C, Monferran S, Malric L, Zentkowski D, Lubrano V, Toulas C, Cohen-Jonathan Moyal E, Lemarie A.

Cell Death Dis. 2014 Nov 27;5:e1543. doi: 10.1038/cddis.2014.509.

18.

Preclinical evidence that SSR128129E--a novel small-molecule multi-fibroblast growth factor receptor blocker--radiosensitises human glioblastoma.

Ader I, Delmas C, Skuli N, Bonnet J, Schaeffer P, Bono F, Cohen-Jonathan-Moyal E, Toulas C.

Eur J Cancer. 2014 Sep;50(13):2351-9. doi: 10.1016/j.ejca.2014.05.012. Epub 2014 Jun 18.

PMID:
24953334
19.

Int6/eIF3e is essential for proliferation and survival of human glioblastoma cells.

Sesen J, Cammas A, Scotland SJ, Elefterion B, Lemarié A, Millevoi S, Mathew LK, Seva C, Toulas C, Moyal EC, Skuli N.

Int J Mol Sci. 2014 Jan 29;15(2):2172-90. doi: 10.3390/ijms15022172.

20.

Radiation-induced mitotic cell death and glioblastoma radioresistance: a new regulating pathway controlled by integrin-linked kinase, hypoxia-inducible factor 1 alpha and survivin in U87 cells.

Lanvin O, Monferran S, Delmas C, Couderc B, Toulas C, Cohen-Jonathan-Moyal E.

Eur J Cancer. 2013 Sep;49(13):2884-91. doi: 10.1016/j.ejca.2013.05.003. Epub 2013 Jun 6.

PMID:
23747271
21.

αvβ3 Integrin and Fibroblast growth factor receptor 1 (FGFR1): Prognostic factors in a phase I-II clinical trial associating continuous administration of Tipifarnib with radiotherapy for patients with newly diagnosed glioblastoma.

Ducassou A, Uro-Coste E, Verrelle P, Filleron T, Benouaich-Amiel A, Lubrano V, Sol JC, Delisle MB, Favre G, Ken S, Laprie A, De Porre P, Toulas C, Poublanc M, Cohen-Jonathan Moyal E.

Eur J Cancer. 2013 Jun;49(9):2161-9. doi: 10.1016/j.ejca.2013.02.033. Epub 2013 Apr 6.

PMID:
23566417
22.

Decreased efficiency of MSH6 mRNA polyadenylation linked to a 20-base-pair duplication in Lynch syndrome families.

Decorsière A, Toulas C, Fouque F, Tilkin-Mariamé AF, Selves J, Guimbaud R, Chipoulet E, Delmas C, Rey JM, Pujol P, Favre G, Millevoi S, Vagner S.

Cell Cycle. 2012 Jul 1;11(13):2578-80. doi: 10.4161/cc.20625. Epub 2012 Jul 1. No abstract available.

PMID:
22672937
23.

Simplified identification of Lynch syndrome: a prospective, multicenter study.

Bonnet D, Selves J, Toulas C, Danjoux M, Duffas JP, Portier G, Kirzin S, Ghouti L, Carrère N, Suc B, Alric L, Barange K, Buscail L, Chaubard T, Imani K, Guimbaud R.

Dig Liver Dis. 2012 Jun;44(6):515-22. doi: 10.1016/j.dld.2011.12.020. Epub 2012 Apr 3.

PMID:
22480969
24.

Rare germline large rearrangements in the BRCA1/2 genes and eight candidate genes in 472 patients with breast cancer predisposition.

Rouleau E, Jesson B, Briaux A, Nogues C, Chabaud V, Demange L, Sokolowska J, Coulet F, Barouk-Simonet E, Bignon YJ, Bonnet F, Bourdon V, Bronner M, Caputo S, Castera L, Delnatte C, Delvincourt C, Fournier J, Hardouin A, Muller D, Peyrat JP, Toulas C, Uhrhammer N, Vidal V, Stoppa-Lyonnet D, Bieche I, Lidereau R.

Breast Cancer Res Treat. 2012 Jun;133(3):1179-90. doi: 10.1007/s10549-012-2009-5. Epub 2012 Apr 5.

PMID:
22476849
25.

Colon-specific phenotype in Lynch syndrome associated with EPCAM deletion.

Grandval P, Baert-Desurmont S, Bonnet F, Bronner M, Buisine MP, Colas C, Noguchi T, North MO, Rey JM, Tinat J, Toulas C, Olschwang S.

Clin Genet. 2012 Jul;82(1):97-9. doi: 10.1111/j.1399-0004.2011.01826.x. Epub 2012 Jan 16. No abstract available.

PMID:
22243433
26.

The prognostic significance of lymphovascular invasion on biopsy specimens in lung cancer treated with definitive chemoradiotherapy.

Massabeau C, Filleron T, Wakil G, Rouquette I, Bachaud JM, Leguellec S, Delisle MB, Toulas C, Mazieres J, Cohen-Jonathan Moyal E.

Clin Lung Cancer. 2012 Jan;13(1):59-67. doi: 10.1016/j.cllc.2011.06.011.

PMID:
21856239
27.

Association of the variants CASP8 D302H and CASP10 V410I with breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers.

Engel C, Versmold B, Wappenschmidt B, Simard J, Easton DF, Peock S, Cook M, Oliver C, Frost D, Mayes R, Evans DG, Eeles R, Paterson J, Brewer C; Epidemiological Study of Familial Breast Cancer (EMBRACE), McGuffog L, Antoniou AC, Stoppa-Lyonnet D, Sinilnikova OM, Barjhoux L, Frenay M, Michel C, Leroux D, Dreyfus H, Toulas C, Gladieff L, Uhrhammer N, Bignon YJ, Meindl A, Arnold N, Varon-Mateeva R, Niederacher D, Preisler-Adams S, Kast K, Deissler H, Sutter C, Gadzicki D, Chenevix-Trench G, Spurdle AB, Chen X, Beesley J; Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab), Olsson H, Kristoffersson U, Ehrencrona H, Liljegren A; Swedish Breast Cancer Study, Sweden (SWE-BRCA), van der Luijt RB, van Os TA, van Leeuwen FE; Hereditary Breast and Ovarian cancer group Netherlands (HEBON), Domchek SM, Rebbeck TR, Nathanson KL, Osorio A, Ramón y Cajal T, Konstantopoulou I, Benítez J, Friedman E, Kaufman B, Laitman Y, Mai PL, Greene MH, Nevanlinna H, Aittomäki K, Szabo CI, Caldes T, Couch FJ, Andrulis IL, Godwin AK, Hamann U, Schmutzler RK; Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA).

Cancer Epidemiol Biomarkers Prev. 2010 Nov;19(11):2859-68. doi: 10.1158/1055-9965.EPI-10-0517. Epub 2010 Oct 26.

28.

A novel germline CHEK2 deletion truncating the kinase domain identified in a French family with high-risk of breast/ovarian cancer.

Escudie P, Monteil-Onteniente S, Gladieff L, Feillel V, Guimbaud R, Favre G, Toulas C.

Breast Cancer Res Treat. 2010 Feb;120(1):267-70. doi: 10.1007/s10549-009-0551-6. Epub 2009 Sep 19. No abstract available.

PMID:
19768534
29.

The c.5242C>A BRCA1 missense variant induces exon skipping by increasing splicing repressors binding.

Millevoi S, Bernat S, Telly D, Fouque F, Gladieff L, Favre G, Vagner S, Toulas C.

Breast Cancer Res Treat. 2010 Apr;120(2):391-9. doi: 10.1007/s10549-009-0392-3. Epub 2009 Apr 30.

PMID:
19404736
30.

Basic fibroblast growth factor-2/beta3 integrin expression profile: signature of local progression after chemoradiotherapy for patients with locally advanced non-small-cell lung cancer.

Massabeau C, Rouquette I, Lauwers-Cances V, Mazières J, Bachaud JM, Armand JP, Delisle MB, Favre G, Toulas C, Cohen-Jonathan-Moyal E.

Int J Radiat Oncol Biol Phys. 2009 Nov 1;75(3):696-702. doi: 10.1016/j.ijrobp.2008.11.050. Epub 2009 Apr 20.

PMID:
19386436
31.

Alphavbeta3/alphavbeta5 integrins-FAK-RhoB: a novel pathway for hypoxia regulation in glioblastoma.

Skuli N, Monferran S, Delmas C, Favre G, Bonnet J, Toulas C, Cohen-Jonathan Moyal E.

Cancer Res. 2009 Apr 15;69(8):3308-16. doi: 10.1158/0008-5472.CAN-08-2158. Epub 2009 Apr 7.

32.

Alphavbeta3 and alphavbeta5 integrins control glioma cell response to ionising radiation through ILK and RhoB.

Monferran S, Skuli N, Delmas C, Favre G, Bonnet J, Cohen-Jonathan-Moyal E, Toulas C.

Int J Cancer. 2008 Jul 15;123(2):357-364. doi: 10.1002/ijc.23498.

33.

Phase I trial of tipifarnib (R115777) concurrent with radiotherapy in patients with glioblastoma multiforme.

Moyal EC, Laprie A, Delannes M, Poublanc M, Catalaa I, Dalenc F, Berchery D, Sabatier J, Bousquet P, De Porre P, Alaux B, Toulas C.

Int J Radiat Oncol Biol Phys. 2007 Aug 1;68(5):1396-401. Epub 2007 Jun 14.

PMID:
17570606
34.

The contribution of germline rearrangements to the spectrum of BRCA2 mutations.

Casilli F, Tournier I, Sinilnikova OM, Coulet F, Soubrier F, Houdayer C, Hardouin A, Berthet P, Sobol H, Bourdon V, Muller D, Fricker JP, Capoulade-Metay C, Chompret A, Nogues C, Mazoyer S, Chappuis P, Maillet P, Philippe C, Lortholary A, Gesta P, Bézieau S, Toulas C, Gladieff L, Maugard CM, Provencher DM, Dugast C, Delvincourt C, Nguyen TD, Faivre L, Bonadona V, Frébourg T, Lidereau R, Stoppa-Lyonnet D, Tosi M.

J Med Genet. 2006 Sep;43(9):e49.

35.

Activation of RhoB by hypoxia controls hypoxia-inducible factor-1alpha stabilization through glycogen synthase kinase-3 in U87 glioblastoma cells.

Skuli N, Monferran S, Delmas C, Lajoie-Mazenc I, Favre G, Toulas C, Cohen-Jonathan-Moyal E.

Cancer Res. 2006 Jan 1;66(1):482-9.

36.

Breast cancer risk in BRCA1 and BRCA2 mutation carriers and polyglutamine repeat length in the AIB1 gene.

Hughes DJ, Ginolhac SM, Coupier I, Barjhoux L, Gaborieau V, Bressac-de-Paillerets B, Chompret A, Bignon YJ, Uhrhammer N, Lasset C, Giraud S, Sobol H, Hardouin A, Berthet P, Peyrat JP, Fournier J, Nogues C, Lidereau R, Muller D, Fricker JP, Longy M, Toulas C, Guimbaud R, Yannoukakos D, Mazoyer S, Lynch HT, Lenoir GM, Goldgar DE, Stoppa-Lyonnet D, Sinilnikova OM.

Int J Cancer. 2005 Nov 1;117(2):230-3.

37.

Farnesylated RhoB inhibits radiation-induced mitotic cell death and controls radiation-induced centrosome overduplication.

Milia J, Teyssier F, Dalenc F, Ader I, Delmas C, Pradines A, Lajoie-Mazenc I, Baron R, Bonnet J, Cohen-Jonathan E, Favre G, Toulas C.

Cell Death Differ. 2005 May;12(5):492-501.

38.

Common BRCA2 variants and modification of breast and ovarian cancer risk in BRCA1 mutation carriers.

Hughes DJ, Ginolhac SM, Coupier I, Corbex M, Bressac-de-Paillerets B, Chompret A, Bignon YJ, Uhrhammer N, Lasset C, Giraud S, Hardouin A, Berthet P, Peyrat JP, Fournier J, Nogues C, Lidereau R, Muller D, Fricker JP, Longy M, Toulas C, Guimbaud R, Maugard C, Olschwang S, Yannoukakos D, Durocher F, Moisan AM, Simard J, Mazoyer S, Lynch HT, Szabo C, Lenoir GM, Goldgar DE, Stoppa-Lyonnet D, Sinilnikova OM.

Cancer Epidemiol Biomarkers Prev. 2005 Jan;14(1):265-7.

39.

The farnesyltransferase inhibitor R115777 reduces hypoxia and matrix metalloproteinase 2 expression in human glioma xenograft.

Delmas C, End D, Rochaix P, Favre G, Toulas C, Cohen-Jonathan E.

Clin Cancer Res. 2003 Dec 1;9(16 Pt 1):6062-8.

40.

Inhibition of Rho pathways induces radiosensitization and oxygenation in human glioblastoma xenografts.

Ader I, Delmas C, Bonnet J, Rochaix P, Favre G, Toulas C, Cohen-Jonathan-Moyal E.

Oncogene. 2003 Dec 4;22(55):8861-9.

PMID:
14654782
41.

Two prognostic groups of inflammatory breast cancer have distinct genotypes.

Lerebours F, Bertheau P, Bieche I, Plassa LF, Champeme MH, Hacene K, Toulas C, Espie M, Marty M, Lidereau R.

Clin Cancer Res. 2003 Sep 15;9(11):4184-9.

42.

BRCA1 wild-type allele modifies risk of ovarian cancer in carriers of BRCA1 germ-line mutations.

Ginolhac SM, Gad S, Corbex M, Bressac-De-Paillerets B, Chompret A, Bignon YJ, Peyrat JP, Fournier J, Lasset C, Giraud S, Muller D, Fricker JP, Hardouin A, Berthet P, Maugard C, Nogues C, Lidereau R, Longy M, Olschwang S, Toulas C, Guimbaud R, Yannoukakos D, Szabo C, Durocher F, Moisan AM, Simard J, Mazoyer S, Lynch HT, Goldgar D, Stoppa-Lyonnet D, Lenoir GM, Sinilnikova OM.

Cancer Epidemiol Biomarkers Prev. 2003 Feb;12(2):90-5.

43.
44.

Increased expression of a COOH-truncated nucleophosmin resulting from alternative splicing is associated with cellular resistance to ionizing radiation in HeLa cells.

Dalenc F, Drouet J, Ader I, Delmas C, Rochaix P, Favre G, Cohen-Jonathan E, Toulas C.

Int J Cancer. 2002 Aug 20;100(6):662-8.

45.

RhoB controls the 24 kDa FGF-2-induced radioresistance in HeLa cells by preventing post-mitotic cell death.

Ader I, Toulas C, Dalenc F, Delmas C, Bonnet J, Cohen-Jonathan E, Favre G.

Oncogene. 2002 Sep 5;21(39):5998-6006.

46.

Farnesyltransferase inhibitor, R115777, reverses the resistance of human glioma cell lines to ionizing radiation.

Delmas C, Heliez C, Cohen-Jonathan E, End D, Bonnet J, Favre G, Toulas C.

Int J Cancer. 2002 Jul 1;100(1):43-8.

47.

Inhibition of human tumor cell growth in vivo by an orally bioavailable inhibitor of human farnesyltransferase, BIM-46228.

Prevost GP, Pradines A, Brezak MC, Lonchampt MO, Viossat I, Ader I, Toulas C, Kasprzyk P, Gordon T, Favre G, Morgan B.

Int J Cancer. 2001 Mar 1;91(5):718-22.

48.

The farnesyltransferase inhibitor FTI-277 suppresses the 24-kDa FGF2-induced radioresistance in HeLa cells expressing wild-type RAS.

Cohen-Jonathan E, Toulas C, Ader I, Monteil S, Allal C, Bonnet J, Hamilton AD, Sebti SM, Daly-Schveitzer N, Favre G.

Radiat Res. 1999 Oct;152(4):404-11.

PMID:
10477917
49.

Prognostic value of uPA and p53 accumulation measured by quantitative biochemical assays in 1245 primary breast cancer patients: a multicentre study.

Broët P, Spyratos F, Romain S, Quillien V, Daver A, Ricolleau G, Rallet A, Toulas C, Asselain B.

Br J Cancer. 1999 May;80(3-4):536-45.

50.

Radioresistance induced by the high molecular forms of the basic fibroblast growth factor is associated with an increased G2 delay and a hyperphosphorylation of p34CDC2 in HeLa cells.

Cohen-Jonathan E, Toulas C, Monteil S, Couderc B, Maret A, Bard JJ, Prats H, Daly-Schveitzer N, Favre G.

Cancer Res. 1997 Apr 1;57(7):1364-70.

Supplemental Content

Loading ...
Support Center